Neurocrine Biosciences — Jul 30, 2026 release

• At June 30, 2026, the Company had cash, cash equivalents, and marketable securities totaling approximately $482 million. Full Year 2026 Financial Guidance (dollars in millions) Prior Updated INGREZZA Net Product Sales 1 $2,700 - $2,800 $2,825 - $2,875 GAAP R&D 2 $1,200 - $1,250 $1,275 - $1,325 Non-GAAP R&D 2, 3 $1,110 - $1,160 $1,140 - $1,190 IPR&D 4 $20 $23 GAAP SG&A 5 $1,375 - $1,400 $1,575 - $1,600 Non-GAAP SG&A 3, 5 $1,240 - $1,265 $1,325 - $1,350 GAAP Amortization of Acquired Intangible Assets 6 Not applicable $85 - $90 1. INGREZZA sales guidance reflects expected net product sales of INGREZZA in tardive dyskinesia and chorea associated with Huntington’s disease. 2. R&D guidance reflects the continued advancement of the Company’s pre-clinical and clinical portfolio including the Phase 3 programs for osavampator in MDD and direclidine in schizophrenia, and includes approximately $25 million of expense for development milestones related to our in-licensed product candidates. Development milestones are included in R&D guidance once achieved or deemed probable to achieve. 3. Non-GAAP guidance has been adjusted to exclude estimated non-cash stock-based compensation expense of approximately $115 million in R&D and $170 million in SG&A, including approximately $58 million related to the acceleration of vesting of equity awards for Soleno employees which vested in full upon the closing of the transaction, and acquisition, integration and divestiture-related expenses of app